仁济医院发表全球首个CAR-T细胞治疗晚期肝细胞癌成果 - 2020年05月15日

Local experts have completed the world’s first phase-1 clinical trial on CAR-T treatment for terminal liver cancer. Their research was published in the journal Clinical Cancer Research.
A patient formerly diagnosed with terminal liver cancer has been living with the disease for nearly five years without being detected with cancerous changes and has normal data on liver cancer biomarkers, said experts from Renji Hospital of Shanghai Jiao Tong University School of Medicine on Wednesday.
CAR-T, or Chimeric Antigen Receptor T-Cell Immunotherapy, is a type of immunotherapy that uses a patient’s own immunity against cancer while not hurting healthy cells.